Home - Pureos Bioventures
What we do Team Jobs News Contact Close Building tomorrow's antibody-drug conjugates (ADCs) Araris Biotech AG , a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to ‘off-the-shelf’ antibodies in one step without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ADC therapies. Learn more
— Intro to ADC — Araris Linker Technology
Stay in touch ...subscribe to our newsletter
Home - Pureos Bioventures